Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.

MLA

Munro, Alasdair P. S., et al. “Safety, Immunogenicity, and Reactogenicity of BNT162b2 and MRNA-1273 COVID-19 Vaccines given as Fourth-Dose Boosters Following Two Doses of ChAdOx1 NCoV-19 or BNT162b2 and a Third Dose of BNT162b2 (COV-BOOST): A Multicentre, Blinded, Phase 2, Randomised Trial.” Lancet Infectious Diseases, vol. 22, no. 8, Aug. 2022, pp. 1131–41. EBSCOhost, https://doi.org/10.1016/S1473-3099(22)00271-7.

APA

Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., & Kanji, N. (2022). Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, 22(8), 1131–1141. https://doi.org/10.1016/S1473-3099(22)00271-7

Chicago

Munro, Alasdair P S, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, David Baxter, et al. 2022. “Safety, Immunogenicity, and Reactogenicity of BNT162b2 and MRNA-1273 COVID-19 Vaccines given as Fourth-Dose Boosters Following Two Doses of ChAdOx1 NCoV-19 or BNT162b2 and a Third Dose of BNT162b2 (COV-BOOST): A Multicentre, Blinded, Phase 2, Randomised Trial.” Lancet Infectious Diseases 22 (8): 1131–41. doi:10.1016/S1473-3099(22)00271-7.